Global Cancer Gene Therapy Market Growth (Status and Outlook) 2023-2029

Global Cancer Gene Therapy Market Growth (Status and Outlook) 2023-2029

Cancer could be defined as uncontrolled cell growth in the body leading to organ malfunction. If untreated, it can lead to death. Uncontrolled growth of cell is managed by the body in several ways, one of them is by deploying white blood cells to detect and eradicate these cancerous cells. It has been discovered that the immune system could be manipulated to influence cancerous cells to destroy itself.

LPI (LP Information)' newest research report, the “Cancer Gene Therapy Industry Forecast” looks at past sales and reviews total world Cancer Gene Therapy sales in 2022, providing a comprehensive analysis by region and market sector of projected Cancer Gene Therapy sales for 2023 through 2029. With Cancer Gene Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cancer Gene Therapy industry.

This Insight Report provides a comprehensive analysis of the global Cancer Gene Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Cancer Gene Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Cancer Gene Therapy market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cancer Gene Therapy and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cancer Gene Therapy.

The global Cancer Gene Therapy market size is projected to grow from US$ 510.7 million in 2022 to US$ 1674.2 million in 2029; it is expected to grow at a CAGR of 18.5% from 2023 to 2029.

Several unmet medical needs for treatment of cancer have encouraged R&D of cancer gene therapy. Various factors, such as increasing prevalence of cancer, rising government initiatives, increasing funding from various government and non-government organizations, are driving the global cancer gene therapy market. In addition, ethical acceptance of gene therapy for treatment of diseases and growing popularity of DNA vaccines is driving the global cancer gene therapy market. However, less awareness and high cost involved in treatment are restraining the growth of global market for cancer gene therapy.

This report presents a comprehensive overview, market shares, and growth opportunities of Cancer Gene Therapy market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Oncolytic Virotherapy
Gene Transfer
Gene-Induced Immunotherapy

Segmentation by application
Hospitals
Diagnostics Centers
Research Institutes

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Adaptimmune
Bluebird bio
Celgene
Shanghai Sunway Biotech
Shenzhen SiBiono GeneTech
SynerGene Therapeutics
Altor BioScience
Amgen
Argenx
BioCancell
GlaxoSmithKline
Merck
OncoGenex Pharmaceuticals
Transgene

Please note: The report will take approximately 2 business days to prepare and deliver.